Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
95
-
Total 13F shares, excl. options
-
45.4M
-
Shares change
-
+12.9M
-
Total reported value, excl. options
-
$1.14B
-
Value change
-
+$405M
-
Put/Call ratio
-
0.65
-
Number of buys
-
63
-
Number of sells
-
-38
-
Price
-
$25.20
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q1 2021
121 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q1 2021.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 95 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.4M shares
of 108M outstanding shares and own 41.93% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (3.72M shares), Rock Springs Capital Management LP (3.57M shares), Foresite Capital Management IV, LLC (3.4M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.2M shares), RENAISSANCE TECHNOLOGIES LLC (2.99M shares), VANGUARD GROUP INC (2.12M shares), Cormorant Asset Management, LP (2M shares), Foresite Capital Management III, LLC (1.95M shares), Parkman Healthcare Partners LLC (1.71M shares), and Vivo Capital, LLC (1.65M shares).
This table shows the top 95 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.